TransMedics Group, Inc. (NASDAQ: TMDX) said its chief financial officer, Gerardo Hernandez, carried out two separate sales of common stock in early March 2026 that together amounted to about $1.12 million. According to the company’s Form 4 disclosures, the transactions took place on March 2 and March 4.
The filings show Hernandez sold 375 shares on March 2 for $52,170 and subsequently sold 5,912 shares on March 4 for $1,065,211. The sales were executed at a price of $139.12 and at a weighted average price of $147.21, with the individual sale prices reported in the filing ranging from $147.14 to $147.47.
The same Form 4 reveals Hernandez exercised stock options on March 4 to acquire a total of 7,236 shares of TransMedics common stock. Those exercises comprised 1,324 shares at an exercise price of $77.12 and 5,912 shares at an exercise price of $69.84, for a combined exercise value of $515,000.
Following the option exercises and the share disposals, Hernandez is reported to directly own 14,689 shares of TransMedics Group.
The timing of the insider activity is notable relative to recent market moves. TransMedics shares are trading at $130.87, down nearly 9% over the prior week, underscoring short-term volatility in the medical device company’s stock.
Independent analysis from InvestingPro cited in the filing summary indicates the stock appears overvalued relative to its Fair Value, while the company’s financial health received a "GREAT" score under that service’s metrics. The filing notes there are additional InvestingPro Tips available for deeper analysis.
Separately, TransMedics released fourth-quarter 2025 financial results that materially exceeded analyst expectations. The company reported adjusted earnings per share of $2.62, well above the consensus estimate of $0.39. Revenue for the quarter was $160.8 million, topping the anticipated $155.98 million and representing a 32% increase year-over-year.
For 2026, management provided revenue guidance in a range of $727 million to $757 million, implying growth of 20% to 25% year-over-year. The midpoint of that range sits slightly above an analyst consensus cited in the filing of $725 million.
TransMedics also disclosed the accounting impact of a U.S. tax valuation allowance release of $103.3 million, which contributed to a net income tax benefit of $83.8 million in the fourth quarter.
Following the quarter and guidance, analyst firm Needham raised its price target for TransMedics to $174 and maintained a Buy rating. Stifel revised its price target to $130 while also maintaining its rating; Stifel highlighted a strengthening U.S. liver business and potential upside from forthcoming real-world liver data but described the results as mixed, pointing to pressures in operating margins and ongoing clinical trials.
The regulatory disclosures and the company’s recent quarterly performance provide context for Hernandez’s option exercises and subsequent sales. The transactions and the company’s forward guidance were filed publicly via Form 4 and the company’s earnings release, which together capture the quantifiable details of the insider activity and the company’s latest operational and financial signals.